(85 days)
Not Found
No
The document describes a mechanical implant and does not mention any software, algorithms, or data processing that would indicate the use of AI/ML.
Yes
The intended use statement explicitly states that the device is for "reduction or relief of pain and/or improved hip function," which aligns with the definition of a therapeutic device.
No.
The device is an acetabular shell intended for use in cementless total hip arthroplasty to treat various hip conditions, not to diagnose them.
No
The device description clearly states it is a physical implant (Monoblock acetabular cup manufactured from CoCr alloy) intended for surgical implantation, not a software product.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the device is for "cementless total hip arthroplasty for reduction or relief of pain and/or improved hip function in skeletally mature patients." This describes a surgical implant used in vivo (within the body) to treat a physical condition.
- Device Description: The description details a "Monoblock acetabular cup" made from CoCr alloy with a porous bead coating. This is a physical implant designed to be surgically placed in the hip joint.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens (like blood, urine, or tissue) in vitro (outside the body) to provide information about a physiological state, health, or disease.
IVD devices are used to perform tests on samples taken from the body to diagnose, monitor, or screen for diseases or conditions. This device is a surgical implant used to replace a damaged hip joint.
N/A
Intended Use / Indications for Use
The CONSERVE® Thin Shells are intended for use in cementless total hip arthroplasty for reduction or relief of pain and/or improved hip function in skeletally mature patients.
Indications for Use
- non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, 1. ankylosis, protrusio acetabuli, and painful hip dysplasia;
- inflammatory degenerative joint disease such as rheumatoid arthritis; 2.
-
- correction of functional deformity; and,
- revision procedures where other treatments or devices have failed 4.
The CONSERVE® Thin Shell is intended for cementless hip arthroplasty.
Product codes (comma separated list FDA assigned to the subject device)
KWA
Device Description
Design features of the shells are summarized below:
- Monoblock acetabular cup .
- . Available in 12 sizes
- Manufactured from CoCr alloy with a CoCr porous bead coating .
The CONSERVE® Thin Shells are identical to previously cleared devices, except that the subject device does not possess HA coating. Additionally, the CONSERVE® Thin Shells were evaluated via post-impaction analysis of clearance, form and frictional torque. A review of these results indicates that the CONSERVE® Thin Shells are equivalent to predicate devices.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Hip
Indicated Patient Age Range
Skeletally mature patients
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The CONSERVE® Thin Shells were evaluated via post-impaction analysis of clearance, form and frictional torque. A review of these results indicates that the CONSERVE® Thin Shells are equivalent to predicate devices.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3330 Hip joint metal/metal semi-constrained, with an uncemented acetabular component, prosthesis.
(a)
Identification. A hip joint metal/metal semi-constrained, with an uncemented acetabular component, prosthesis is a two-part device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that consist of a femoral and an acetabular component, both made of alloys, such as cobalt-chromium-molybdenum. The femoral component is intended to be fixed with bone cement. The acetabular component is intended for use without bone cement (§ 888.3027).(b)
Classification. Class III.(c)
Date PMA or notice of completion of PDP is required. A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before May 18, 2016, for any hip joint metal/metal semi-constrained prosthesis with an uncemented acetabular component that was in commercial distribution before May 28, 1976, or that has, on or before May 18, 2016, been found to be substantially equivalent to a hip joint metal/metal semi-constrained prosthesis with an uncemented acetabular component that was in commercial distribution before May 28, 1976. Any other hip joint metal/metal semi-constrained prosthesis with an uncemented acetabular component shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
p. 1/2
2012
510(K) Summary of Safety and Effectiveness
In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CFR 807, this information serves as a Summary of Safety and Effectiveness for the use of the CONSERVE® Thin Shell.
| Submitted By: | Wright Medical Technology, Inc.
5677 Airline Rd, Arlington TN, 38002
(800) 238-7188 |
|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Date: | November 9, 2011 |
| Contact Person: | Matt Paul
Project Regulatory Affairs Specialist |
| Proprietary Name: | CONSERVE® Thin Shell |
| Common Name: | Acetabular Cup |
| Classification Name and Reference: | 888.3330 Hip joint metal/metal semi-
constrained, with an uncemented acetabular
component prosthesis
Class I |
| Subject Product Code and Panel Code: | Orthopedics/87/KWA |
| Predicate Devices: | CONSERVE® HA Shells
CONSERVE® Acetabular Shell (cleared as "Metal
TRANSCEND® Articulation System")
510(k)s: K042530, K021349 |
DEVICE INFORMATION
A. Intended Use
The CONSERVE® Thin Shells are intended for use in cementless total hip arthroplasty for reduction or relief of pain and/or improved hip function in skeletally mature patients.
Indications for Use
- non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, 1. ankylosis, protrusio acetabuli, and painful hip dysplasia;
- inflammatory degenerative joint disease such as rheumatoid arthritis; 2.
-
- correction of functional deformity; and,
- revision procedures where other treatments or devices have failed 4.
The CONSERVE® Thin Shell is intended for cementless hip arthroplasty.
1
B. Device Description
Design features of the shells are summarized below:
- Monoblock acetabular cup .
- . Available in 12 sizes
- Manufactured from CoCr alloy with a CoCr porous bead coating .
The CONSERVE® Thin Shells are identical to previously cleared devices, except that the subject device does not possess HA coating. Additionally, the CONSERVE® Thin Shells were evaluated via post-impaction analysis of clearance, form and frictional torque. A review of these results indicates that the CONSERVE® Thin Shells are equivalent to predicate devices.
C. Substantial Equivalence Information
The indications for use of the CONSERVE® Thin Shells are identical to the previously cleared predicate devices. The design features and materials of the subject devices are substantially equivalent to those of the predicate devices. The fundamental scientific technology of the modified devices has not changed relative to the predicate devices. The safety and effectiveness of the CONSERVE® Thin Shells are adequately supported by the substantial equivalence information, materials information, and analysis data provided within this Premarket Notification.
2
Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with its wings spread, symbolizing protection and care. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hamoshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Wright Medical Technology, Incorporated % Mr. Matt Paul Project Regulatory Affairs Specialist 5677 Airline Road Arlington, Tennessee 38002
FEB - 3 2012
Re: K113322
Trade/Device Name: CONSERVE® Thin Shell Regulation Number: 21 CFR 888.3330 Regulation Name: Hip joint metal/metal semi-constrained, with an uncemented acetabular Component, prosthesis Regulatory Class: Class III Product Code: KWA Dated: January 5, 2012 Received: January 6, 2012
Dear Mr. Paul:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
3
Page 2 - Mr. Matt Paul
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHQffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely vours.
Eunel Keith
For Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known):
Device Name: CONSERVE® Thin Shells
Intended Use:
The CONSERVE® Thin Shells are intended for use in total hip arthroplasty for reduction or relief of pain and/or improved hip function in skeletally mature patients.
Indications For Use:
- non-inflammatory degenerative joint disease such as osteoarthritis, avascular 1. . necrosis, ankylosis, protrusio acetabuli, and painful hip dysplasia;
- inflammatory degenerative joint disease such as rheumatoid arthritis; 2.
- correction of functional deformity; and, 3.
- revision procedures where other treatments or devices have failed. 4.
The CONSERVE® Thin Shell is intended for cementless hip arthroplasty.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Ollue
(Division Sign-Off)
ion of Surgical, Orthopedic, and Restorative Devices
510(k) Number K113322